Entia raises £931k for oncology monitoring platform

London-based Entia Ltd has secured a seed funding round of £931k to support its remote patient-monitoring services for oncology. The company, which was incorporated in 2014, developed an at-home full-blood-count analyser designed to predict and prevent side effects from cancer treatments. This technology allows for earlier medical interventions and aims to reduce the number of unplanned hospitalisations for patients at cancer centres.

Financial records for the year ending 31 March 2025 show the business recorded a £4.2m loss. During that period, the company employed 27 people, though more recent data from its LinkedIn profile indicates the headcount has grown to 32. Entia utilizes artificial intelligence and machine learning to identify patients at risk of complications, partnering with global oncology centres to support various therapies.

The latest investment coincides with the notification of Kadmos Medtech I Limited as a person with significant control. This corporate entity now holds between 25% and 50% of the company's shares and voting rights. No previous funding rounds were compared against this seed stage filing, which was documented in August 2026.

In August 2026, Remy Kesrouani was appointed as a director of the company. LinkedIn information suggests Kesrouani may be a Managing Partner at Kadmos Capital Ltd. The allotment of shares for this round also occurred in August 2026.